{"id":"direct-acting-oral-anticoagulation","safety":{"commonSideEffects":[{"rate":"2-4% major bleeding annually","effect":"Bleeding (major and minor)"},{"rate":"1-2%","effect":"Gastrointestinal bleeding"},{"rate":"5-11%","effect":"Dyspepsia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"0.3-0.8%","effect":"Intracranial hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug class includes Factor IIa inhibitors (dabigatran) and Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban), which directly block key enzymes in the coagulation cascade. By inhibiting these factors, DOACs prevent the conversion of prothrombin to thrombin or reduce Factor Xa activity, thereby reducing clot formation without requiring monitoring of INR levels like warfarin.","oneSentence":"Direct-acting oral anticoagulants inhibit specific clotting factors (either Factor IIa or Factor Xa) to prevent thrombus formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:23.981Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Acute coronary syndrome (in combination with antiplatelet therapy)"}]},"trialDetails":[{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT05472766","phase":"NA","title":"Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-11-24","conditions":"Subdural Hematoma, Atrial Fibrillation","enrollment":1},{"nctId":"NCT04437303","phase":"PHASE4","title":"Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2020-11-25","conditions":"Aortic Valve Disease, Aortic Valve Stenosis, Stroke","enrollment":858},{"nctId":"NCT05292846","phase":"PHASE4","title":"Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures","status":"UNKNOWN","sponsor":"Hospital Universitario La Fe","startDate":"2022-01-20","conditions":"Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction","enrollment":200},{"nctId":"NCT05088928","phase":"PHASE2","title":"Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care","status":"UNKNOWN","sponsor":"Scotmann Pharmaceuticals","startDate":"2022-03-01","conditions":"COVID-19","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Direct-acting oral anticoagulation","genericName":"Direct-acting oral anticoagulation","companyName":"Hospital Universitario La Fe","companyId":"hospital-universitario-la-fe","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct-acting oral anticoagulants inhibit specific clotting factors (either Factor IIa or Factor Xa) to prevent thrombus formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}